Open Access

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor‑positive/progesterone receptor‑negative breast cancer

  • Authors:
    • Helena Fohlin
    • Tove Bekkhus
    • Josefine Sandström
    • Tommy  Fornander
    • Bo Nordenskjöld
    • John Carstensen
    • Olle Stål
  • View Affiliations

  • Published online on: March 9, 2020     https://doi.org/10.3892/mco.2020.2014
  • Pages: 415-420
  • Copyright: © Fohlin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemically untreated patients with estrogen receptor (ER)‑positive/progesterone receptor (PR)‑negative tumors with high Ras‑related protein Rab‑6C (RAB6C) expression levels (RAB6C+) had prolonged distant recurrence‑free survival compared with that of patients exhibiting low RAB6C (RAB6C‑)‑expressing tumors. The aim of the present study was to investigate whether RAB6C predicts the effectiveness of tamoxifen treatment. The present study used a dataset comprising 486 female patients with ER+ tumors from a randomized study conducted by the Stockholm Breast Cancer Study Group between November 1976 and August 1990. The patients were considered as low‑risk if their tumor size was ≤30 mm and their lymph node status was negative. Patients were followed up until distant recurrence, mortality or when 25 years after randomization was achieved, whichever occurred first. For patients with ER+/PR‑/RAB6C+ tumors, prolonged distant recurrence‑free survival could not be observed if the patients were treated with tamoxifen [hazard ratio (HR), 1.82; 95% confidence interval (CI), 0.69‑4.79; P=0.23], whereas patients with ER+/PR‑/RAB6C‑ tumors had 75% reduced distant recurrence risk (HR, 0.25; 95% CI, 0.09‑0.70; P=0.008). In the ER+/PR+ subgroup, patients with RAB6C‑ and RAB6C+ tumors benefited from tamoxifen treatment, though it was most evident in the RAB6C+ group (HR, 0.27; 95% CI, 0.13‑0.58; P=0.001). The results of the present study indicated that, for patients with ER+/PR‑ tumors, those with low RAB6C expression benefited from tamoxifen treatment, whereas no benefit was observed in patients with high RAB6C levels.
View Figures
View References

Related Articles

Journal Cover

May 2020
Volume 12 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Fohlin, H., Bekkhus, T., Sandström, J., Fornander, T., Nordenskjöld, B., Carstensen, J., & Stål, O. (2020). Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor‑positive/progesterone receptor‑negative breast cancer. Molecular and Clinical Oncology, 12, 415-420. https://doi.org/10.3892/mco.2020.2014
MLA
Fohlin, H., Bekkhus, T., Sandström, J., Fornander, T., Nordenskjöld, B., Carstensen, J., Stål, O."Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor‑positive/progesterone receptor‑negative breast cancer". Molecular and Clinical Oncology 12.5 (2020): 415-420.
Chicago
Fohlin, H., Bekkhus, T., Sandström, J., Fornander, T., Nordenskjöld, B., Carstensen, J., Stål, O."Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor‑positive/progesterone receptor‑negative breast cancer". Molecular and Clinical Oncology 12, no. 5 (2020): 415-420. https://doi.org/10.3892/mco.2020.2014